Articles related to OPIOIDS

Originally published in JAMA Psychiatry, a broad-based study shows nearly 7% of OUD patients are adding buprenorphine to urine sample to fake treatment adherence. Buprenorphine spiking suggests to the physician that the treatment plan is not working—especially in patients continuing illicit drug use.

According to the FDA, more than 101,000 fatal overdoses were reported during the 12-month period that ended in October 2022. Nearly half of fatal overdoses involve bystanders, but naloxone is only used in a small percentage of those situations. According to medical professionals who support the approval, there would be a critical opportunity to close this gap and lower the number of opioid-related deaths if naloxone were available over-the-counter.

The DEA has issued a warning after discovering xylazine, a tranquilizer for large animals, in almost 25% of the fentanyl powder it seized in 2022. Extensive, necrotic skin ulcerations brought on by xylazine can even result in amputation due to the drug’s ability to impair breathing and cause overdoses. The Combating Illicit Xylazine Act would reclassify the drug as a Schedule III drug, designate it as an emerging threat, and give the DEA the ability to monitor the drug’s production.

Anyone who handles controlled substances must review their policies and procedures for identifying suspect prescriptions and taking appropriate action when necessary. Safe controlled substance (CS) handling procedures must also be followed by manufacturers and distributors. Thankfully, pharmacies can use tactics to spot questionable prescriptions, evade DEA inspections, and—most importantly—protect the health of their customers. But what comes first? Understanding what a red-flag prescription is.

Nearly 25% of fentanyl powder seized in 48 states in 2022 contained xylazine. Xylazine causes severe injection site wounds that can require amputation and puts drug users at higher risk for overdose and death.

Pandemic-era telemedicine exceptions that currently allow telehealth prescription of Schedule II narcotics and stimulants without an initial in-person evaluation are to be ended on May 11.